Asthma – Landscape & Forecast – Disease Landscape & Forecast
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva, Novartis’s Enerzair); oral drugs (e.g., montelukast); and biologics (e.g., GlaxoSmithKline’s Nucala, Sanofi / Regeneron’s Dupixent). The impending approval and launch of additional biological therapies, branded generic and generic inhaled drugs, and LABA/LAMA/ICS combination agents for asthma will further increase the competition in this market.
Questions answered
- What insights do thought leaders have on current inhaled branded, branded generic, and generic treatment options? What is the current and future market impact of branded generic and generic inhaled therapies?
- What are key opinion leaders’ perceptions of currently marketed asthma biologics (Nucala, Dupixent, Roche / Novartis’s Xolair, Teva’s Cinqair / Cinqaero, AstraZeneca’s Fasenra, AstraZeneca / Amgen’s Tezspire)? What drives physicians’ choice of a biologic for severe refractory asthma?
- How will the market evolve over the next 10 years given the launch of additional inhaled, oral, and biological products? What effect will the entry of the triple LABA/LAMA/ICS combination agents have on the sales and patient share of current therapies? Where do physicians see these triple therapies fitting in the treatment algorithm?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: ~20 country-specific interviews with thought leaders.
Epidemiology: Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent / mild persistent and moderate / severe persistent asthma.
Drug treatments: Coverage of key current and emerging therapies
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Asthma - Landscape & Forecast - Disease Landscape & Forecast
- Executive Summary
- Key Updates
- Market Forecast
- Key takeaways
- Market drivers and constraints
- Drug class-specific trends
- Inhaled corticosteroids
- Long-acting beta2 agonists
- Long-acting beta2 agonist / inhaled corticosteroid combinations
- Long-acting muscarinic antagonists
- Long-acting beta2 agonists / long-acting muscarinic antagonists / inhaled corticosteroid fixed-dose combinations
- Methylxanthines
- Leukotriene inhibitors
- Tyrosine kinase inhibitors
- Anti-immunoglobin E agents
- Anticytokines
- Oral corticosteroids
- Short-acting bronchodilators
- Short-acting bronchodilator / inhaled corticosteroid combinations
- Market Forecast Assumptions
- Market Forecast Dashboard
- Key takeaways
- Disease Context
- Epidemiology
- Current Treatment
- Key takeaways
- Treatment for asthma
- Key current therapies
- Inhaled corticosteroids
- Long-acting beta2 agonists
- LABA/ICS fixed-dose combinations
- Leukotriene inhibitors
- Long-acting muscarinic antagonists
- Long-acting beta2 agonist / long-acting muscarinic antagonist / inhaled corticosteroid fixed-dose combinations
- Anti-immunoglobulin E agents
- IL-5 antagonists
- IL-4 / IL-13 antagonists
- TSLP antagonists
- Short-acting beta2 agonists
- Short-acting beta2 agonist / inhaled corticosteroid fixed-dose combinations
- Key takeaways
- Emerging Therapies
- Drug Pipeline
- Appendix
- Executive Summary
